Biogen climbs on early Alzheimer's data

Biogen Idec Inc. (NASDAQ:BIIB) gained $42.33 (10%) to $475.98 on Friday after reporting detailed Phase Ib data for Alzheimer's disease (AD) candidate aducanumab ( BIIB037).

Aducanumab led to statistically significant reductions in beta amyloid levels and reduced cognitive decline in multiple dose cohorts of 30-33 patients each with prodromal or mild AD. Data were presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France. ...